Preethi William
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Preethi William has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Hoang Nhat Pham
Department of Medicine, University of Arizona, Tucson, USA
2 shared publicationsAhmad Safdar
Department of Medicine, Cleveland Clinic , 9500 Euclid Ave, Cleveland, OH 44195
1 shared publicationAmanda R. Vest
Department of Medicine, University of Arizona, Tucson, USA
1 shared publicationDanial Hassan
Harvard TH Chan School of Public Health , 677 Huntington Ave, Boston, MA 02115
1 shared publicationFahad Ahmad
Sindh Institute of Urology and Transplantation , Chand Bibi Rd, Ranchore Lane, Karachi, Karachi City, Sindh
1 shared publicationMohammad Shahzad Asif
Department of Medicine, University College of Medicine and Dentistry , Lahore, Punjab, Pakistan
1 shared publication
Latest Publications
- Open Access
- 28 August 2024
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 26 (12) , 355-367
Managing Obesity in Heart Failure: Latest Evidence and Knowledge Gaps
Purpose of Review: This review aims to synthesize the latest evidence focused on therapies related to comorbid obesity and heart failure, with particular attention to lifestyle, pharmacological, and surgical modalities. Recent Findings: Obesity is a common risk factor for heart failure, which can also exacerbate symptom burden of heart failure. Emerging treatments, such as the use of GLP-1 analogs like semaglutide, have shown promising results in improving symptoms and physical limitations in the setting of comorbid heart failure with preserved ejection fraction and obesity. Conversely, the efficacy of such treatments in heart failure with reduced ejection fraction remains uncertain, with some studies suggesting potential adverse outcomes. Lifestyle interventions, including dietary changes and structured exercise programs, may be associated with benefits in terms of functional capacity and symptom burden, and retrospective cohort studies of surgical weight loss have raised the possibility of improvements in medium term survival for patients with baseline HF, challenging the previous notions of the "obesity survival paradox”. Summary: The management of comorbid obesity and heart failure is a rapidly evolving field. The interplay of pharmacological, lifestyle, and surgical interventions highlights the need for personalized treatment plans to mitigate the risks and enhance the quality of life for patients with heart failure. It is hoped that future guidelines will integrate these findings to address the nuances of optimally treating both heart failure and obesity in patients with both conditions. Graphical
- 28 August 2024
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 26 (12) , 355-367
Open AccessManaging Obesity in Heart Failure: Latest Evidence and Knowledge Gaps
Purpose of Review: This review aims to synthesize the latest evidence focused on therapies related to comorbid obesity and heart failure, with particular attention to lifestyle, pharmacological, and surgical modalities. Recent Findings: Obesity is a common risk factor for heart failure, which can also exacerbate symptom burden of heart failure. Emerging treatments, such as the use of GLP-1 analogs like semaglutide, have shown promising results in improving symptoms and physical limitations in the setting of comorbid heart failure with preserved ejection fraction and obesity. Conversely, the efficacy of such treatments in heart failure with reduced ejection fraction remains uncertain, with some studies suggesting potential adverse outcomes. Lifestyle interventions, including dietary changes and structured exercise programs, may be associated with benefits in terms of functional capacity and symptom burden, and retrospective cohort studies of surgical weight loss have raised the possibility of improvements in medium term survival for patients with baseline HF, challenging the previous notions of the "obesity survival paradox”. Summary: The management of comorbid obesity and heart failure is a rapidly evolving field. The interplay of pharmacological, lifestyle, and surgical interventions highlights the need for personalized treatment plans to mitigate the risks and enhance the quality of life for patients with heart failure. It is hoped that future guidelines will integrate these findings to address the nuances of optimally treating both heart failure and obesity in patients with both conditions. Graphical
- 3 June 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 10 (6) , 547-556
Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies that evaluated the clinical efficacy and safety of various agents used in ATTR-CM, with a goal of identifying the contemporary gaps in literature and to reveal future research opportunities. Methods and results: The search was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search using several databases for observational and clinical trials investigating the treatment modalities for ATTR-CM was undertaken. We extracted data including study characteristics, primary endpoints, and adverse events from each study. A total of 19 studies were included in our scoping review. Out of which, 8 were clinical trials and 11 were observational analyses. The drugs evaluated included tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid and doxycycline, diflusinil, inotersan, eplontersen, and patisiran. Tafamidis has shown to be efficacious in the management of ATTR-CM, particularly when initiated at earlier stages. RNA interference and antisense oligonucleotide drugs have shown promising impacts on quality of life. Additionally, this review identified gaps in the literature, particularly among long-term outcomes, comparative effectiveness, and the translation of research into economic contexts. Conclusion: Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM. However, many gaps exist in the understanding of these various drug therapies, warranting further research. The future directions for management of ATTR-CM are promising in regard to improving prognostic implications.
- 3 June 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 10 (6) , 547-556
Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review
Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the accumulation of transthyretin (TTR) protein in the myocardium. The aim of this scoping review is to provide a descriptive summary of the clinical trials and observational studies that evaluated the clinical efficacy and safety of various agents used in ATTR-CM, with a goal of identifying the contemporary gaps in literature and to reveal future research opportunities. Methods and results: The search was performed in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A literature search using several databases for observational and clinical trials investigating the treatment modalities for ATTR-CM was undertaken. We extracted data including study characteristics, primary endpoints, and adverse events from each study. A total of 19 studies were included in our scoping review. Out of which, 8 were clinical trials and 11 were observational analyses. The drugs evaluated included tafamadis, acoramidis, revusiran, doxycycline and tauroursodeoxycholic acid and doxycycline, diflusinil, inotersan, eplontersen, and patisiran. Tafamidis has shown to be efficacious in the management of ATTR-CM, particularly when initiated at earlier stages. RNA interference and antisense oligonucleotide drugs have shown promising impacts on quality of life. Additionally, this review identified gaps in the literature, particularly among long-term outcomes, comparative effectiveness, and the translation of research into economic contexts. Conclusion: Multiple pharmacological options are potential disease-modifying therapies for ATTR-CM. However, many gaps exist in the understanding of these various drug therapies, warranting further research. The future directions for management of ATTR-CM are promising in regard to improving prognostic implications.